We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 11, 2018

Liraglutide Decreases Cardiovascular Event Risk in Patients With Type 2 Diabetes and Chronic Kidney Disease



Additional Info

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes and Chronic Kidney Disease: Results From the LEADER Trial
Circulation 2018 Oct 03;[EPub Ahead of Print], JFE Mann, V Fonseca, O Mosenzon, I Raz, B Goldman, T Idorn, BJ von Scholten, NR Poulter

Further Reading